---
schema_version: "secwatch.filing_event.v1"
accession: "0001711279-25-000048"
form_type: "8-K"
ticker: "KRYS"
cik: "0001711279"
company_name: "Krystal Biotech, Inc."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T16:34:47.069730+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Krystal Biotech presents preclinical data for KB111 (HHD) and KB112 (Darier) at SID 2025

## Summary
- KB111 targets ATP2C1 for Hailey-Hailey disease; KB112 targets ATP2A2 for Darier disease.
- Both HSV-1-based vectors transduced keratinocytes with dose-dependent target protein expression and no cytotoxicity.
- KB111 functionally corrected ATP2C1 siRNA knockdown in keratinocytes, reversing F-actin loss (p<0.05).
- Topical administration in mice showed proper localization of ATP2C1 and ATP2A2 with minimal toxicity.

## SEC filing metadata
- accession: 0001711279-25-000048
- form_type: 8-K
- ticker: KRYS
- cik: 0001711279
- company_name: Krystal Biotech, Inc.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711279/000171127925000048/0001711279-25-000048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711279/000171127925000048/krys-20250512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001711279-25-000048
- JSON: https://secwatch.observer/filing/0001711279-25-000048.json
- Plain text: https://secwatch.observer/filing/0001711279-25-000048.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.